RxDoctor Payments Data

Joshua Stein, MD

Ophthalmology · Ann Arbor, MINPI 1992885073

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Ocular Therapeutix, Inc. at 59.0% of the total. Reporting peaked in 2023 at $79 and has fallen 56.8% since, to $34 in 2024. That places this record below the midpoint for ophthalmology clinicians in MI, where the typical reported total is $1,066.

$144in general payments, 2019–2025

Across 6 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$85
  • Thea Pharma Inc.$34
  • Alcon$25
$200,000in research payments, 2019–2025

Across 3 payments — averaging $66,667 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ocular Therapeutix, Inc.$200K

What the payments were for

  • Food & beverage$144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ocular Therapeutix, Inc.4$85
Thea Pharma Inc.1$34
Alcon1$25

How this compares

$144 in reported general payments places this provider in the 15th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$35,529
Medicare patients
142
Services billed
674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate53$21,274
Brimonidine Tartrate104$13,354
LumiganBimatoprost32$9,572
CombiganBrimonidine Tartrate/Timolol17$7,911
SimbrinzaBrinzolamide/Brimonidine Tart23$6,646
Latanoprost229$4,622
Dorzolamide-TimololDorzolamide/Timolol/Pf12$3,996
VyzultaLatanoprostene Bunod13$3,884
Travoprost16$3,725
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat127$3,426
Timolol Maleate100$3,212
Dorzolamide Hcl73$2,182
Prednisolone Acetate39$1,660
Ketorolac Tromethamine49$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$25$6,64623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →